Controlled Release from Porous Platforms - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Controlled Release from Porous Platforms
The authors present a method for controlling the release of therapeutics by applying a plasma polymer layer to the surface of porous materials.

Pharmaceutical Technology
Volume 35, Issue 8, pp. 68-71


The authors described a method for controlled release of therapeutics from porous materials that has the potential to be applied to various therapeutics and types of porous materials. The method involves the application of a plasma-polymer layer on top of porous materials, and the thickness of this layer controls release kinetics. Athough the current study emphasizes plasma polymerization as a tool to reduce pore diameter at the surface, future work should consider the influence of the plasma polymer's physical properties, such as hydrophilicity, on drug release. The ability of plasma polymerization to provide films of various physical and chemical properties provides enormous flexibility for fine tuning drug-release platforms to suit various drugs and applications.

Spomenka Simovic is a doctor of colloid chemistry and pharmaceutics, Dusan Losic is associate professor of nanostructured materials, and Krasimir Vasilev* is an Australian Future fellow, all at the University of South Australia, Mawson Lakes Campus, 5095 Mawson Lakes, South Australia, fax: +61 8 830 25689,

*To whom all correspondence should be addressed.

Submitted: Feb. 17, 2011. Accepted: May 13, 2011


1. C.T. Kresge et al., Nature 359, 710–712 (1992).

2. J.S. Beck et al., J. Am. Chem. Soc. 114 (27), 10834–10843 (1992).

3. M. Vallet-Regi et al., Chem. Mater. 13 (2), 308–311 (2001).

4. M. Vallet-Regi, F. Balas, and D. Arcos, Angew. Chem. Int. Ed. 46, 7548–7558 (2007).

5. K.C. Popat et al., Biomater. 28 (21), 3188–3197 (2007).

6. M. Vallet-Regi, Chem. Eur. J. 12, 5934–5943 (2006).

7. I. Izquierdo-Barba and M. Vallet-Regi, J. Nanomater. 1, 1–14, (2008).

8. L. Peng et al., Biomater. 30 (7), 1268–1272 (2009).

9. L. Peng et al., Nano Lett. 9 (5), 1932-1936 (2009).

10. K.E. La Flamme et al., Cell Transplant. 16, 765–774 (2007).

11. K.E. La Flamme et al., Biomater. 28 (16), 2638–2645 (2007).

12. E.E. Leary Swan, K.C. Popat, and T.A. Desai, Biomater. 26 (14), 1969–1976 (2005).

13. K.C. Popat et al., Biomater. 26 (22), 4516–4522 (2005).

14. H. Masuda and K. Fukuda, Science 268, 1466–1468 (1995).

15. P. Costa and J. M. Sausa-Lobo, Eur. J. Pharm. Sci. 13 (2), 123–133 (2001).

16. S. Simovic, D. Losic, and K. Vasilev. Chem. Commun. 46, 1317–1319 (2010).

17. K. Vasilev et al., Chem. Commun. 24, 3600–3602 (2009).

18. A.J. Beck et al., Tissue Eng. 7 (4), 441–456 (2003).

19. K. Vasilev et al., Nano Lett. 10 (1), 202–207 (2010).

20. D. Losic et al., Nanotechnol. 19, (2008).

21. F. Balas et al., J. Am. Chem. Soc. 128, 8116–8117 (2006).

Citation: When referring to this article, please cite it as "S. Simovic; D. Losic; K. Vasilev, "Controlled Release from Porous Platforms," Pharmaceutical Technology 35 (8) 68-71(2011)."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here